ATE298246T1 - Aktiviertes protein c zur behandlung von pankreatitis - Google Patents
Aktiviertes protein c zur behandlung von pankreatitisInfo
- Publication number
- ATE298246T1 ATE298246T1 AT01918217T AT01918217T ATE298246T1 AT E298246 T1 ATE298246 T1 AT E298246T1 AT 01918217 T AT01918217 T AT 01918217T AT 01918217 T AT01918217 T AT 01918217T AT E298246 T1 ATE298246 T1 AT E298246T1
- Authority
- AT
- Austria
- Prior art keywords
- activated protein
- pancreatitis
- treatment
- disease
- pathological condition
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 206010033645 Pancreatitis Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 101800004937 Protein C Proteins 0.000 abstract 2
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 abstract 2
- 101800001700 Saposin-D Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 229960000856 protein c Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19275500P | 2000-03-28 | 2000-03-28 | |
| PCT/US2001/005823 WO2001072328A2 (en) | 2000-03-28 | 2001-03-21 | Methods of treating diseases with activated protein c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE298246T1 true ATE298246T1 (de) | 2005-07-15 |
Family
ID=22710924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01918217T ATE298246T1 (de) | 2000-03-28 | 2001-03-21 | Aktiviertes protein c zur behandlung von pankreatitis |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1267915B1 (de) |
| JP (1) | JP2003528153A (de) |
| AT (1) | ATE298246T1 (de) |
| AU (1) | AU2001245319A1 (de) |
| CA (1) | CA2404231A1 (de) |
| DE (1) | DE60111620T2 (de) |
| ES (1) | ES2242740T3 (de) |
| PT (1) | PT1267915E (de) |
| WO (1) | WO2001072328A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6841371B2 (en) | 2000-02-02 | 2005-01-11 | Eli Lilly And Company | Protein C derivatives |
| JP2003521938A (ja) | 2000-02-11 | 2003-07-22 | イーライ・リリー・アンド・カンパニー | プロテインc誘導体 |
| AU2002302192B2 (en) * | 2001-06-13 | 2007-08-16 | Zz Biotech Llc | Treatment and composition for wound healing |
| DE10158561A1 (de) * | 2001-11-29 | 2003-06-12 | Bayer Ag | Neue Verwendung von Cyclopentabenzofuranen |
| ES2504365T3 (es) * | 2002-12-05 | 2014-10-08 | Zz Biotech L.L.C. | La actividad neuroprotectora de la proteína C activada es independiente de su actividad anticoagulante |
| EP1651252B1 (de) * | 2003-07-08 | 2014-11-26 | The Scripps Research Institute | Aktivierte protein c varianten mit normaler zytoprotektiver aktivität aber verringerter gerinnungshemmender aktivität |
| US9192657B2 (en) | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| IN2014DN10075A (de) * | 2012-05-31 | 2015-08-21 | Univ Kinki | |
| ES2676422T3 (es) * | 2012-07-04 | 2018-07-19 | Zz Biotech Llc | Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel |
| PT3131572T (pt) | 2014-04-16 | 2021-09-24 | Zz Biotech Llc | Análogo de apc para utilização em cicatrização de feridas |
| ES2890675T3 (es) * | 2014-04-16 | 2022-01-21 | Zz Biotech Llc | APC para uso en el tratamiento de cicatrices cutáneas anormales |
| EP3160504B1 (de) * | 2014-06-24 | 2020-09-16 | Immunomedics, Inc. | Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| JP4256497B2 (ja) * | 1998-08-06 | 2009-04-22 | 旭化成ファーマ株式会社 | 血管炎治療剤 |
| JP2000219633A (ja) * | 1999-01-29 | 2000-08-08 | Chemo Sero Therapeut Res Inst | 虚血性腎障害の予防・治療剤 |
-
2001
- 2001-03-21 AU AU2001245319A patent/AU2001245319A1/en not_active Abandoned
- 2001-03-21 JP JP2001570289A patent/JP2003528153A/ja active Pending
- 2001-03-21 AT AT01918217T patent/ATE298246T1/de not_active IP Right Cessation
- 2001-03-21 ES ES01918217T patent/ES2242740T3/es not_active Expired - Lifetime
- 2001-03-21 CA CA002404231A patent/CA2404231A1/en not_active Abandoned
- 2001-03-21 WO PCT/US2001/005823 patent/WO2001072328A2/en not_active Ceased
- 2001-03-21 EP EP01918217A patent/EP1267915B1/de not_active Expired - Lifetime
- 2001-03-21 DE DE60111620T patent/DE60111620T2/de not_active Expired - Lifetime
- 2001-03-21 PT PT01918217T patent/PT1267915E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001245319A1 (en) | 2001-10-08 |
| JP2003528153A (ja) | 2003-09-24 |
| EP1267915B1 (de) | 2005-06-22 |
| DE60111620T2 (de) | 2006-05-18 |
| ES2242740T3 (es) | 2005-11-16 |
| WO2001072328A2 (en) | 2001-10-04 |
| DE60111620D1 (de) | 2005-07-28 |
| CA2404231A1 (en) | 2001-10-04 |
| WO2001072328A3 (en) | 2002-02-14 |
| EP1267915A2 (de) | 2003-01-02 |
| PT1267915E (pt) | 2005-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE411399T1 (de) | Behandlung der huntington's krankheit mit epa | |
| DE69822665D1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| DE60328476D1 (de) | Medizinisches ballonsystem zur behandlung von adipositas | |
| EA200500856A1 (ru) | Новые химические соединения | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| DE602004017037D1 (de) | 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose | |
| EP1302542A4 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| DE60231107D1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| DE60111620D1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
| DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
| EA200500934A1 (ru) | Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний | |
| ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
| ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| DE69736180D1 (de) | Behandlung von manischen erkrankungen | |
| ATE285764T1 (de) | Rivastigmine zur behandlung von augenerkrankungen | |
| DE60128084D1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl | |
| ATE343387T1 (de) | S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen. | |
| ATE516038T1 (de) | Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen | |
| EP1143996A4 (de) | Methode zur behandlung von chronischen herzerkrankungen | |
| DE69905489D1 (de) | Protein c zur behandlung von sichelzellanämie und thalassämie | |
| DE60302495D1 (de) | Landwirtschaftliche Maschine zur Behandlung von Erntegut |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1267915 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |